Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia

Documenti analoghi

• Leukocyte Surface Biomarkers for Clinical Diagnosis of Sporadic Alzheimer’s Disease
  di: Abe Durrant, et al.
  Pubblicazione: (2024)
• Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study
  di: Riccardo Perfetti, et al.
  Pubblicazione: (2024)
• Breaking down the influences of placebo progression and percent slowing on the observed treatment difference in Alzheimer’s Disease clinical trials for populations in different disease stages
  di: Caleb W Dayley, et al.
  Pubblicazione: (2025)
• Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease
  di: Garrett B Duncan, et al.
  Pubblicazione: (2025)
• Galactosemia como causa de ictericia neonatal
  di: Mery Yolanda Cifuentes-Cifuentes
  Pubblicazione: (2014)